BriaCell Therapeutics Corp. ("BriaCell" or the "Company")
(TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology
company specializing in targeted immunotherapy for advanced breast
cancer, today announced early efficacy data of BriaCell’s novel
immunotherapy, Bria-IMT™, in combination with pembrolizumab
[KEYTRUDA®; manufactured by Merck & Co., Inc. (NYSE: MRK)] (the
“Combination Study”) in advanced breast cancer patients.
Detailed findings are included below, with early evidence
suggesting rapid additive or synergistic anti-tumor activity
including examples of tumor reduction at multiple sites and disease
stabilization. Additionally, the combination was very safe and
well-tolerated in all 6 patients of the study.
BriaCell had hypothesized that combining
Bria-IMT™, which "puts the foot on the gas" of the immune system,
with immune “checkpoint inhibitors”, such as KEYTRUDA®, which act
by "awakening" a component of the immune system, would lead to more
powerful anti-cancer activity compared to Bria-IMT™ alone.
Initial efficacy data for the first six patients supports
BriaCell’s hypothesis. For Bria-IMT™ alone in monotherapy study,
HLA matching between the patient and Bria-IMT™ appeared to be
important for the development of anti-cancer activity, but the
combination with KEYTRUDA® appears to overcome this limitation.
Summary of Early Data of Bria-IMT™ with
KEYTRUDA® Combination Study
- All 6 patients were very heavily pre-treated with a median of 5
prior systemic therapy regimens (such as chemotherapy) prior to
enrollment in BriaCell’s Combination Study.
- These patients previously did not respond to a number of
currently available therapies outside of BriaCell, and most had
very weak immune systems, further emphasizing the importance of the
positive results observed in BriaCell’s Combination Study.
Efficacy Data
Four patients rolled-over from BriaCell’s Bria-IMT™ monotherapy
study:
- Top Responder: One woman with stable disease on monotherapy had
been on 8 prior chemotherapy regimens and had extensive tumor
growth in her liver. She experienced a 43% reduction in the
size of her liver metastases within 2 months and continues on the
Combination Study.
- She had a tumor type that typically does not respond to
KEYTRUDA® alone, suggesting distinct benefits by the Combination
Study.
- Of note, she is not an HLA match with Bria-IMT™ suggesting that
the combination with KEYTRUDA® may not require a ‘match with
Bria-IMT™’ to result in tumor reduction. Consequently, the
Combination Study regimen may work for patients regardless of HLA
matching.
- Three women had progressive disease prior to the Combination
Study – they were only dosed for a short time, and either
discontinued the treatment or showed progressive disease.
They had very weak immune systems and very advanced cancer prior to
BriaCell’s Combination Study.
Two patients entered the Combination Study
directly without previous Bria-IMT™ treatment:
- One woman achieved stable disease, in spite of 9 prior
anti-cancer regimens (including 6 chemotherapy regimens and 3
biological therapy regimens) and therefore appears to have derived
clinical benefit from the combination treatment. She matched
Bria-IMT™ at one HLA allele (“type”).
Safety Data
The combination was very safe and well-tolerated
in all 6 patients of the study.
"Early results from the Combination Study of
Bria-IMT™ with KEYTRUDA® in advanced breast cancer have revealed
that anti-tumor activity of BriaCell’s novel immunotherapy,
Bria-IMT™, can be further enhanced with KEYTRUDA®," stated Dr. Bill
Williams, BriaCell’s president and CEO. "We are impressed with the
early data of the Combination Study, suggesting efficacy and
clinical benefits in a heavily-treated, difficult to treat patient
population. One woman for example experienced a robust immune
response to Bria-IMT™ before starting the combination study, and
her tumor-reduction response to Bria-IMT™ was significantly
enhanced when Bria-IMT™ was combined with KEYTRUDA®. We look
forward to the continuation of the Combination Study and hope to be
able to offer better treatment solutions for advanced breast cancer
patients. We would like to thank our consultants and patients
who make these findings possible in the fight against this
devastating disease."
About Phase I/IIa Combination Study of
Bria-IMT™ with KEYTRUDA® in Advanced Breast Cancer
The FDA has approved the combination study of
Bria-IMT™ with KEYTRUDA®, an anti-PD-1 antibody, for patients with
advanced breast cancer. More information on the Combination
Study of Bria-IMT™ with KEYTRUDA® will be available on
ClinicalTrials.gov
(https://clinicaltrials.gov/ct2/show/NCT03328026).
About KEYTRUDA®
(pembrolizumab)
Manufactured by Merck & Co., Inc., KEYTRUDA®
(pembrolizumab) is a prescription medicine that may treat certain
cancers by working with the immune system. It has been approved for
the treatment of a number of cancer indications, excluding breast
cancer. For more information on pembrolizumab, please see:
http://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf.
About AACR
The AACR was founded in Washington, D.C., May 7,
1907, by a group of 11 physicians and scientists intending “to
further the investigation and spread the knowledge of cancer.” To
prevent and cure cancer using research, education, communication,
collaboration, funding and advocacy has been the mission of AACR.
With its programs and services, AACR advances research in cancer
and related biomedical science by facilitating exchange of
knowledge and innovations among scientists and clinicians dedicated
to the fight against cancer, providing education and training in
oncology treatment and advancing cancer etiology, prevention, early
detection, diagnosis and treatment worldwide.
For more information on AACR, please visit:
https://www.aacr.org.
About BriaCell
BriaCell is an immuno-oncology focused
biotechnology company developing targeted and safe approaches for
the management of cancer.
BriaCell is currently conducting a Phase I/IIa
clinical trial of Bria-IMT™, its lead candidate, in a Combination
Study with pembrolizumab [KEYTRUDA®; manufactured by Merck &
Co., Inc. (NYSE: MRK)]. The Combination Study is listed in
ClinicalTrials.gov as NCT03328026.
BriaCell is developing Bria-OTS™, an
off-the-shelf personalized immunotherapy, for advanced breast
cancer. Bria-OTS™ immunotherapy treatments are personalized to
match the patient without the need for personalized manufacturing.
Bria-OTS™, which is expected to cover over 99 percent of the
patient population, is designed to produce a potent and selective
immune response against the cancer of each patient while
eliminating the time, expense and complex manufacturing logistics
associated with other personalized immunotherapies.
For additional information on BriaCell, please
visit: https://briacell.com/.
Cautionary Note Regarding Forward-Looking
Information
Except for the statements of historical fact,
this news release contains "forward-looking information" within the
meaning of the applicable Canadian securities legislation which
involves known and unknown risks relevant to the Company in
particular and to the biotechnology and pharmaceutical industries
in general, uncertainties and other factors that may cause actual
events to differ materially from current expectation. These risks
are more fully described in the Company's public filings available
at www.sedar.com.
Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. The Company disclaims any
intention or obligation, except to the extent required by law, to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contact Information
For further information, please
contact:BriaCell Therapeutics Corp.:Farrah
DeanManager, Corporate DevelopmentEmail: Farrah@BriaCell.com Phone:
1-888-485-6340
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Apr 2023 to Apr 2024